If you have been reading about research chemical and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
The research assistant's job can include some or all of the following: providing the local institutional review board (IRB) with the documentation necessary to obtain its permission to conduct the study, assisting with study start-up, identifying eligible patients, obtaining consent from them or their families, administering study treatment(s), collecting and statistically analyzing data, maintaining and updating data files during followup, and communicating with the IRB, as well as the sponsor and CRO.
Navacaprant (developmental code names include BTRX-335140, BTRX-140, CYM-53093, NMRA-335140, and NMRA-140) is a selective κ-opioid receptor (KOR) antagonist which is under development for the treatment of major depressive disorder and bipolar depression. It was originated by BlackThorn Therapeutics and is being developed by Neumora Therapeutics. As of February 2025, navacaprant is in phase 3 clinical trials for major depressive disorder. In January 2025, it was disclosed that navacaprant had failed to show effectiveness for major depressive disorder in a phase 3 trial. Upon this announcement, the stock price of Neumora Therapeutics decreased by 80%.
=== Legal status === Eptinezumab was approved for medical use in the United States in February 2020. In November 2021, the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the granting of a marketing authorization for the medicinal product Vyepti, intended for the prophylaxis of migraine. The applicant for this medicinal product is H. Lundbeck A/S. Eptinezumab was approved for medical use in the European Union in January 2022.
Inductive effects and mesomeric effects affect the pKa values. A simple example is provided by the effect of replacing the hydrogen atoms in acetic acid by the more electronegative chlorine atom. The electron-withdrawing effect of the substituent makes ionisation easier, so successive pKa values decrease in the series 4.7, 2.8, 1.4, and 0.7 when 0, 1, 2, or 3 chlorine atoms are present. The Hammett equation, provides a general expression for the effect of substituents.
The Cold War between the "West" (the United States, Western Europe, and Japan) and the "East" (the Soviet Union, Eastern Europe, and China) dominated politics from the end of World War II in 1945, until the collapse of the Soviet Union in 1991, at which point the Cold War ended and the post–Cold War era began (which includes most of the 1990s). The Korean War, Vietnam War, Soviet–Afghan War, and Gulf War, impacted political life, while the counterculture of the 1960s and the rise of computers changed society in different, complex ways, including higher social and local mobility.
Sources: en.wikipedia.org
== Musical style == In an interview with MTV in 2006, vocalist Taylor said that Come What(ever) May was a return to the roots of the band, stating it is "a lot more from the spirit of what the band started with in 1992". He noted that some songs were "very atmospheric" while others maintained "the hard rock and the heavy stuff". Jon Wiederhorn of MTV said that "for every thrash riff there's a tunefully grungy passage, for every flailing guitar line there's a rock-radio hook." When talking about the track "30/30-150", he said parts are "bludgeoning, barbed and heavy" while others are "soaring and triumphant" with the production of Raskulinecz helping to balance the album's heaviness with its radio-accessibility. Come What(ever) May's lyrics include themes of "pain, pleasure, happiness, and grief". The diversity in subjects is evident throughout the album; songs including "Come What(ever) May" were politically influenced while the track "Socio" is about "social anxiety attacks" that Taylor suffered. "Zzyzx Rd" is a love song written to Taylor's wife for helping him in his struggles against alcoholism and contemplation of suicide. "I've never written anything like that before, but it was very important for me to tell the world not only how much she saved me, but how much she means to me," said Taylor. Taylor said there is a common thread with the lyrics throughout the album, saying that they are "about never forgetting where you came from, who you are and why you do this."
The European Bioinformatics Institute (EMBL-EBI) is an intergovernmental organization (IGO) which, as part of the European Molecular Biology Laboratory (EMBL) family, focuses on research and services in bioinformatics. It is located on the Wellcome Genome Campus in Hinxton near Cambridge, and employs over 600 full-time equivalent (FTE) staff. Further, the EMBL-EBI hosts training programs that teach scientists the fundamentals of the work with biological data and promote the plethora of bioinformatic tools available for their research, both EMBL-EBI-based and not so. One of the roles of the EMBL-EBI is to index and maintain biological data in a set of databases, including Ensembl (housing whole genome sequence data), UniProt (protein sequence and annotation database) and Protein Data Bank (protein and nucleic acid tertiary structure database). A variety of online services and tools is provided, such as Basic Local Alignment Search Tool (BLAST) or Clustal Omega sequence alignment tool, enabling further data analysis.
Mangum co-founded the Melbourne Research Unit for Facial Disorders at the Royal Children's Hospital and the University of Melbourne. He was Peter Doherty Fellow and Head of the Translational Proteomics Laboratory from 2014 to 2020, contributing to fields including dental enamel research, cerebrospinal fluid biomarker discovery, and metastatic cancer resistance mechanisms. He has published over 30 peer-reviewed articles and is listed as inventor on more than 20 patents internationally. Mangum co-founded Incisive Technologies in 2012 and led the development of its lead product, BlueCheck™, from initial research through to GMP manufacturing and market clearance. He was Chief Executive Officer (2018–2021) and Chief Scientific Officer (2018–2024), overseeing regulatory strategy, manufacturing scale-up, clinical trials, and scientific marketing. He designed the company's ISO 13485–certified Melbourne facility and led successful funding rounds totalling over AUD $20 million.
12(S)-HpETE and 12(S)-HETE induce itching responses when injected into the skin of mice; this has led to the suggestion that these metabolites contribute to the itching (i.e. clinical pruritus) which accompanies such conditions as atopic dermatitis, contact dermatitis, urticaria, chronic renal failure, and cholestasis. Since it mediates 12(S)-HETE-induced itching in the mouse model, BLT2 rather than GPR31 may mediate human itch in these reactions.
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.